Explore the Australian Prescriber issue: Volume 47 Issue 5.

The October issue of Australian Prescriber addresses 2 challenges in clinical practice: medicine shortages and inhaler devices for people with asthma or chronic obstructive pulmonary disease (COPD).

Our latest news features a valediction as Australian Prescriber farewells Dr Ruth Sutherland from the Editorial Advisory Committee. The 2024 National Medicines Symposium focus is on the safe and appropriate use of medicines in an ageing population.

The new issue also highlights a reflection on community antimicrobial prescribing as the AURA surveillance program reaches almost 10 years of data. Finally, 4 new drug comments are included – avacopan for ANCA-associated vasculitis, clascoterone for acne, and fezolinetant and prasterone for menopausal symptoms.

Explore the October issue:

• Inhaler device selection for people with asthma or COPD
• Managing medicine shortages
• Reflections on community antimicrobial use in Australia
• Immune checkpoint inhibitors and immune-related adverse events

New drugs:

• Avacopan for antineutrophil cytoplasmic antibody–associated vasculitis
• Clascoterone for acne
• Fezolinetant for menopause symptoms
• Prasterone for vulvar and vaginal atrophy in postmenopausal women

Australian Prescriber is Australia’s free, national, independent peer-reviewed journal providing critical commentary on drugs and therapeutics. Published bimonthly, it supports health professionals to make informed choices when prescribing.

The next Australian Prescriber Podcast episode will be released on 29 October 2024. If you haven’t already, listen to the latest episodes on Achieving safe medication management during transitions of care from hospital and on Management of occupational exposure to blood and body fluids in primary care.

Are you a subscriber? Get the latest updates for free. Subscribe now.